Icariin, a potential T2DM therapeutic, improved pancreatic cell function (Jiang et al., 2023) via activation of the AMPK/GLUT-4 pathway (Li et al., 2020). This evidence concerns the gene SLC2A4 and type 2 diabetes mellitus.